Advanced Solid TumoursPhase 1EGRETNCT05647122
First in Human Study of AZD9592 in Solid Tumors
A Phase 1 study testing AZD9592, Osimertinib and 5-Fluorouracil (5-FU) in people with Advanced Solid Tumours and Carcinoma Non-small Cell Lung, run by AstraZeneca at 46 sites in 11 countries.
Trial summary
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms
- What is being tested?
- AZD9592, Osimertinib and 5-Fluorouracil (5-FU)
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 190 participants
- Where
- 46 sitesin 11 countries
- Study dates
- 21 Dec 2022to 3 Aug 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
- Life expectancy ≥ 12 weeks
- Measurable disease per RECIST v1.1
- Adequate organ and marrow function as defined in the protocol
- Additional Inclusion Criteria for Module 1:
Show all 11Show fewer
- Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC; metastatic EGFRwt. NSCLC; recurrent or metastatic HNSCC of the oral cavity; metastatic CRC.
- Additional Inclusion Criteria for Module 2:
- Histologically or cytologically confirmed metastatic NSCLC EGFRmut.
- Additional Inclusion Criteria for Module 3:
- Histologically or cytologically confirmed metastatic CRC.
Who cannot join
- History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Spinal cord compression or a history of leptomeningeal carcinomatosis.
- Active infection including tuberculosis and HBV, HCV or HIV
- Brain metastases unless treated (prior treatment required only for Module 1), asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 2 weeks prior to start of study treatment.
- Participants with cardiac comorbidities as defined in the study protocol
Trial locations and contacts
46 sites in 11 countries.
46 sites in 11 countries
United States15 sites
Research Site
Baltimore, Maryland, 21224
Research Site
Baltimore, Maryland, 21231
Research Site
Chicago, Illinois, 60637
Research Site
Duarte, California, 91010
Research Site
Fairfax, Virginia, 22031
Research Site
Houston, Texas, 77030
Research Site
Milford, Massachusetts, 01757
Research Site
Mineola, New York, 11501
Research Site
New York, New York, 10016
Research Site
New York, New York, 10021
Research Site
New York, New York, 10029
Research Site
North Haven, Connecticut, 06473
Research Site
Philadelphia, Pennsylvania, 19104
Research Site
Providence, Rhode Island, 02903
Research Site
Washington D.C., District of Columbia, 20016
China4 sites
Research Site
Beijing, 100142
Research Site
Chongqing, 400030
Research Site
Guangzhou, 510100
Research Site
Wuhan, 430048
Italy4 sites
Research Site
Milan, 20162
Research Site
Orbassano, 10043
Research Site
Rozzano, 20089
Research Site
Verona, 37134
South Korea4 sites
Research Site
Seoul, 03080
Research Site
Seoul, 03722
Research Site
Seoul, 05505
Research Site
Seoul, 06351
Taiwan4 sites
Research Site
Taichung, 40705
Research Site
Taipei, 10002
Research Site
Taipei, 11217
Research Site
Taoyuan, 333
France3 sites
Research Site
Marseille, 13385
Research Site
Rennes, 35000
Research Site
Villejuif, 94805
Japan3 sites
Research Site
Chūōku, 104-0045
Research Site
Kashiwa, 277-8577
Research Site
Kōtoku, 135-8550
Spain3 sites
Research Site
Barcelona, 8035
Research Site
Madrid, 28040
Research Site
Seville, 41013
Canada2 sites
Research Site
Edmonton, Alberta, T6G 1Z2
Research Site
Toronto, Ontario, M5G 1X6
Malaysia2 sites
Research Site
Kuala Lumpur, 59100
Research Site
Kuching, 93586
About this study
Official title: A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Being tested
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab
- Keywords
- Cancer, First in Human, Antibody Drug Conjugate, Solid Tumour, Phase I
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AZD9592Drug
Varying doses of AZD9592
OsimertinibDrug
tablets administered orally
5-Fluorouracil (5-FU)Drug
IV infusion
LeucovorinDrug
IV infusion
BevacizumabDrug
IV infusion
| Study group | Role | What they receive |
|---|---|---|
| Module 1 AZD9592 Monotherapy | Experimental | Module 1 has two parts:
Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592.
Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 as monotherapy in select solid tumors Receives: Drug: AZD9592 |
| Module 2 AZD9592 Combination with Osimertinib | Experimental | Module 2 has two parts:
Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with Osimertinib.
Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with Osimertinib in NSCLC EGFRm Receives: Drug: AZD9592; Drug: Osimertinib |
| Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin | Experimental | Module 3 has two parts:
Part A aims to determine the safety, tolerability and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) Receives: Drug: AZD9592; Drug: 5-Fluorouracil (5-FU); Drug: Leucovorin; Drug: Bevacizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Adverse Events (AEs)
Number of patients with adverse events by system organ class and preferred term
Measured: From time of Informed Consent to 30 days post last dose of AZD9592
Incidence of Serious Adverse Events (SAEs)
Number of patients with serious adverse events by system organ class and preferred term
Measured: From time of Informed Consent to 30 days post last dose of AZD9592
Incidence of dose-limiting toxicities (DLT) as defined in the protocol
Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
Measured: From time of first dose of AZD9592 to end of DLT period (approximately 21 days)
Incidence of baseline laboratory finding, ECG and vital signs changes
measured by laboratory and vital sign variables over time including change from baseline
Measured: From time of Informed Consent to 30 days post last dose of AZD9592
Proportion of patients with radiological response (ORR)
Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1 (for patients in the dose expansion cohorts, only)
Measured: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Secondary outcomes (12)
Objective Response Rate (ORR)
The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)
Measured: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Duration of Response (DoR)
The time from date of first response until date of disease progression or last evaluable assessment (RECIST v1.1) in the absence of progression
Measured: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Disease Control Rate (DCR) at 12 weeks
The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1) for >=11 weeks from first dose
Measured: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (for each patient this is expected to be measured at 12 weeks)
Progression free Survival (PFS)
The time from first dose until RECIST 1.1 defined disease progression or death due to any cause
Measured: From date of first dose of AZD9592 up until date of progression or death due to any cause (approximately 2 years)
Overall Survival (OS)
The time from the date of the first dose of study treatment until death due to any cause.
Measured: From date of first dose of AZD9592 up until the date of death due to any cause (approximately 2 years)
Pharmacokinetics of AZD9592: Plasma PK concentrations
Measurement of plasma concentrations of AZD9592, total antibody and total unconjugated warhead
Measured: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Area under the concentration time curve (AUC)
Measurement of PK parameters: Area under the concentration time curve (AUC)
Measured: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Maximum plasma concentration of the study drug (C-max)
Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)
Measured: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Time to maximum plasma concentration of the study drug (T-max)
Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)
Measured: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Clearance
Measurement of PK parameters: the volume of plasma from which the study drug is completely removed per unit time (Clearance)
Measured: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Half-life
Measurement of PK parameters: Terminal elimination half-life (t 1/2)
Measured: From date of first dose of AZD9592 up until 30 days post last dose
Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA)
Evaluating the number and percentage of patients who develop Anti-drug antibody (ADA) during treatment
Measured: From date of first dose of AZD9592 up until 30 days post last dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2022
- Study start21 Dec 2022
- Primary completion16 Jun 2026
- Study completion3 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid TumoursStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 190 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Charu Aggarwal, MD, MPH, Principal investigator, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05647122
- Sponsor's protocol ID
- D9350C00001
- Other IDs
- 2022-501570-18-00
- Acronym
- EGRET
- Status last verified
- Sep 2026
- First submitted
- 18 Nov 2022
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
- ClinicalTrials.gov ID
- NCT05647122
- Acronym / sponsor ID
- EGRET / D9350C00001
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Keywords
- Cancer, First in Human, Antibody Drug Conjugate, Solid Tumour, Phase I
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 190 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 21 Dec 2022 (actual)
- Primary completion
- 16 Jun 2026 (actual)
- Study completion
- 3 Aug 2028 (estimated)
- First posted
- 12 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Module 1 AZD9592 Monotherapy | Experimental | Drug: AZD9592Module 1 has two parts: Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592. Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 as monotherapy in select solid tumors |
| Module 2 AZD9592 Combination with Osimertinib | Experimental | Drug: AZD9592, Drug: OsimertinibModule 2 has two parts: Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with Osimertinib. Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with Osimertinib in NSCLC EGFRm |
| Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin | Experimental | Drug: AZD9592, Drug: 5-Fluorouracil (5-FU), Drug: Leucovorin, Drug: BevacizumabModule 3 has two parts: Part A aims to determine the safety, tolerability and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
- Life expectancy ≥ 12 weeks
- Measurable disease per RECIST v1.1
- Adequate organ and marrow function as defined in the protocol
Key exclusion criteria (5 listed)
- History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Spinal cord compression or a history of leptomeningeal carcinomatosis.
- Active infection including tuberculosis and HBV, HCV or HIV
- Brain metastases unless treated (prior treatment required only for Module 1), asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 2 weeks prior to start of study treatment.
- Participants with cardiac comorbidities as defined in the study protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AZD9592Varying doses of AZD9592 | Drug | Module 1 AZD9592 Monotherapy, Module 2 AZD9592 Combination with Osimertinib, Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin |
| Osimertinibtablets administered orally | Drug | Module 2 AZD9592 Combination with Osimertinib |
| 5-Fluorouracil (5-FU)IV infusion | Drug | Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin |
| LeucovorinIV infusion | Drug | Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin |
| BevacizumabIV infusion | Drug | Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin |
Primary outcome
Incidence of Adverse Events (AEs)
Time frame: From time of Informed Consent to 30 days post last dose of AZD9592
Number of patients with adverse events by system organ class and preferred term
Incidence of Serious Adverse Events (SAEs)
Time frame: From time of Informed Consent to 30 days post last dose of AZD9592
Number of patients with serious adverse events by system organ class and preferred term
Incidence of dose-limiting toxicities (DLT) as defined in the protocol
Time frame: From time of first dose of AZD9592 to end of DLT period (approximately 21 days)
Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
Incidence of baseline laboratory finding, ECG and vital signs changes
Time frame: From time of Informed Consent to 30 days post last dose of AZD9592
measured by laboratory and vital sign variables over time including change from baseline
Proportion of patients with radiological response (ORR)
Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1 (for patients in the dose expansion cohorts, only)
12 secondary outcomes
Objective Response Rate (ORR)
Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Duration of Response (DoR)
Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Disease Control Rate (DCR) at 12 weeks
Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (for each patient this is expected to be measured at 12 weeks)
Progression free Survival (PFS)
Time frame: From date of first dose of AZD9592 up until date of progression or death due to any cause (approximately 2 years)
Overall Survival (OS)
Time frame: From date of first dose of AZD9592 up until the date of death due to any cause (approximately 2 years)
Pharmacokinetics of AZD9592: Plasma PK concentrations
Time frame: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Area under the concentration time curve (AUC)
Time frame: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Maximum plasma concentration of the study drug (C-max)
Time frame: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Time to maximum plasma concentration of the study drug (T-max)
Time frame: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Clearance
Time frame: From date of first dose of AZD9592 up until 30 days post last dose
Pharmacokinetics of AZD9592: Half-life
Time frame: From date of first dose of AZD9592 up until 30 days post last dose
Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA)
Time frame: From date of first dose of AZD9592 up until 30 days post last dose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
Related trials for Advanced Solid Tumours
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
A Study of MGC030 in Participants With Advanced Solid Tumors
Urothelial Cancer, GastroEsophageal Cancer
RecruitingPhase 1
SW-682 in Advanced Solid Tumors
Advanced Solid Tumor, Mesothelioma, Malignant
RecruitingPhase 1
Study of XB010 in Subjects With Solid Tumors
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charu Aggarwal, MD, MPH principal investigator
University of Pennsylvania
46 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AZD9592, Osimertinib and 5-Fluorouracil (5-FU) in people with Advanced Solid Tumours and Carcinoma Non-small Cell Lung, run by AstraZeneca at 46 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 46 sites in United States, China, Italy, South Korea, Taiwan and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Adverse Events (AEs) (time frame: From time of Informed Consent to 30 days post last dose of AZD9592). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.